Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.11984
Peer-review started: May 7, 2015
First decision: June 2, 2015
Revised: July 19, 2015
Accepted: September 14, 2015
Article in press: September 14, 2015
Published online: November 14, 2015
Core tip: Chronic hepatitis C virus (HCV) infection occurs in about 75%-90% of acutely infected individuals. It may progress to liver cirrhosis or hepatocellular carcinoma. Despite satisfactory progress in the management and treatment of chronic hepatitis C, it remains one of the most prominent viral infections worldwide. Although no reliable vaccine for it has yet been developed, researchers are trying to design and develop different types of vaccines to prevent HCV infection or to cure the chronic form of the disease. The current article provides an overview of the latest progress in the development of preventive and therapeutic vaccines against HCV infection in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines, and viral vectors expressing HCV genes.